Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Operations (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Cash from Operations for 9 consecutive years, with 98538000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 17.71% to 98538000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 412600000.0 through Dec 2025, down 18.67% year-over-year, with the annual reading at 412600000.0 for FY2025, 18.67% down from the prior year.
  • Cash from Operations for Q4 2025 was 98538000.0 at Denali Therapeutics, up from 107296000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 41434000.0 in Q3 2021, with the low at 131468000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 78719500.0, with a median of 73980500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations crashed 48279.07% in 2021, then surged 32.31% in 2024.
  • Over 5 years, Cash from Operations stood at 65494000.0 in 2021, then decreased by 10.95% to 72663000.0 in 2022, then plummeted by 35.77% to 98657000.0 in 2023, then grew by 15.15% to 83715000.0 in 2024, then decreased by 17.71% to 98538000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 98538000.0, 107296000.0, and 75298000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.